Clinical Trial Update: A Phase Ib/II Clinical Study Evaluating the Safety and Efficacy of Tislelizumab in Combination With Golidocitinib and Selinexor for the Treatment of R/R NKTCL [Phase 1, Phase 2]

View source ↗

Summary

Phase Ib/II clinical study evaluating tislelizumab combined with golidocitinib and selinexor for relapsed/refractory natural killer/T-cell lymphoma (including e…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Extranodal Nk T-cell Lymphoma Nasal Type
• Natural Killer T-cell Lymphoma

Drugs mentioned

• Golidocitinib (golidocitinib)
• Selinexor (selinexor)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: Fudan University | Conditions: Natural Killer/T-cell Lymphoma, Relapsed or Refractory Lymphoma Including ENKL | Phase 1, Phase 2 | Status: RECRUITING